Weekend update: The spinning of Baby Einstein, multiple-med confusion, and more
(UPDATED: See below.)
Revisiting a few life-science stories you might have missed over the weekend:
“Baby Einstein” creator’s defense: We were just kidding! — You have to feel at least a little sorry for Julie Aigner-Clark, the entrepreneur who created the best-selling line of “Baby Einstein” videos for infants and toddlers and then sold her company to Walt Disney five years ago. After University of Washington researchers suggested that the videos may retard language development in babies aged… Continue Reading
Roundup: Biogenerics bill in limbo, clashing data on health IT benefits, the RNAi boom, and more
House-Senate confrontation set over biogenerics – Late last month, a key group of senators reached agreement on legislative provisions that would authorize copycat versions of biotech drugs, which are typically complex proteins manufactured by genetically engineered cells (see details here and here). These provisions would finally put biotech drugs — which don’t face cut-rate competition once their key patents expire — on a par with traditional pharmaceuticals, and have been a long time in coming. They’re… Continue Reading